Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150678 | 0.87 | BTK (1.00) | BTK | |
| SCHEMBL28048298 | 0.85 | BTK (0.68) | BTK | |
| SCHEMBL16150857 | 0.85 | BTK (0.77) | BTK | |
| SCHEMBL28048233 | 0.84 | BTK (0.71) | BTK | |
| SCHEMBL28825408 | 0.81 | BTK (0.70) | BTK | |
| Tert-Butyl Formate SCHEMBL28048300 | 0.79 | BTK (0.60) | BTK | |
| SCHEMBL16151400 | 0.78 | BTK (0.74) | BTK | |
| SCHEMBL16151321 | 0.78 | BTK (0.45) | BTK | |
| SCHEMBL16150452 | 0.78 | BTK (0.81) | BTK | |
| SCHEMBL3065669 | 0.78 | BTK (0.44) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981264-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-2981264-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9617260-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617260-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160280706-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | US | disclosed |
| US-20160280706-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-2981264-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014161799-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014161799-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280706-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.